Category | Insight journal

Bayer hungry for pharma deals to expand business

Posted on 31 October 2014

Big pharma company Bayer , is going hunting for pharma deals again, with its chief executive expected to tell media outlets  that it is looking for further takeover pharma deals. 

Tags: , , ,

Equity firms eye Bayer’s plastic business merger

Posted on 27 October 2014

Private equity firms are circling Bayer’s €10bn plastics business merger, hoping to divert the German drugmaker from its plan to list the division, two people familiar with the matter said yesterday.

Tags: , ,

Both, Actavis and Sanofi competing for Omega Pharma

Posted on 22 October 2014

Several companies are rumored to be competing to acquire Omega Pharma, the fastest growing consumer healthcare company in the U.K. and Ireland.

Tags: ,

Regenerative Medicine deal trends article

Posted on 22 October 2014

The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »

Tags: , ,

Pharmacyclics: Partnering activity 2009-2014

Posted on 20 October 2014

Pharmacyclics, listed as a new big biotech entrant in 2014, works to improve the lives of cancer affected patients by entering into strategic partnering deals to support its product pipeline.

Tags: ,

AbbVie rethinking the $54 billion acquisition of Shire

Posted on 16 October 2014

In response to recent changes to the U.S. tax code to discourage so-called tax inversion deals, Chicago-based AbbVie recently indicated it was rethinking its $54 billion takeover bid of U.K.-based Shire.

Tags: , ,

Actavis chasing Allergan also…which way will Allergan go?

Posted on 15 October 2014

Actavis Plc plans to approach Allergan Inc again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

Current Agreements Deal Analysis Update : October 2014

Posted on 15 October 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in September 2014.

Tags: , , , ,

Nektar Therapeutics: Partnering activity 2009-2014

Posted on 13 October 2014

Nektar Therapeutics is a leading biopharma company headquartered in San Francisco. The company is listed in the top 50 big biotech list by Current Partnering. The company is a world leader in polymer chemistry which involves the design of drugs with optimized drug pharmacology.

Tags: , , ,

Nektar Therapeutics – Well respected partner of choice

Posted on 10 October 2014

Nektar therapeutics is a leading biopharma company developing clinical stage products based upon its advanced polymer conjugate chemistry technology.

Tags: , , ,

bannerpng
wildwood-ventures300x150gif
currentpartneringpharma-bio300x150gif
RSS Feed Linked In Twitter

Latest Tweets

cpbannerad300x150new1gif
wildwood-ventures300x150gif
current-partnering-300x150-orphanjpg